WALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that the company's Board of Directors has appointed Jeremy Gowler as Interim Chief Executive Officer (CEO), effective immediately, while the Board institutes a search for a permanent CEO. Mr. Gowler succeeds Dave Hering. "The Invivyd Board of Directors is positioning the company for its next phase of growth, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 (Exact name of Registrant as specified in its Charter) Delaware 85-1403134 (State or other jurisdiction of incorporation or organization) or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number ...

Exhibit 99.1 Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced financial results for the full year ended December 31, 2023 and recent business highlights. Mr. Hering continued, "With PEMGARDA now authorized and anticipated to be available for order in the U.S. imminently, we are ...

Invivyd, Inc. (NASDAQ:IVVD) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Corporate Participants Scott Young - SVP, Investor Relations and Corporate Communications Dave Hering - Chief Executive Officer Pete Schmidt - Chief Medical Officer Jeremy Gowler - Chief Operating and Commercial Officer Bill Duke - Chief Financial Officer Conference Call Participants Patrick Trucchio - H.C. Wainwright Jenna Li - Jefferies Maxwell Skor - Morgan Stanley Evan Wang - Guggenheim Securities Operator Welcome t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-40703 INVIVYD, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 8 ...

Invivyd, Inc. (NASDAQ:IVVD) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Gabriella Linville-Engler - Investor Relations Dave Hering - Chief Financial Officer Pete Schmidt - Chief Medical Officer Conference Call Participants Maxwell Skor - Morgan Stanley Evan Wang - Guggenheim Patrick Trucchio - H.C. Wainwright Operator Welcome to the Invivyd Second Quarter 2023 Business and Financial Results Update Call. I will now turn the call over to Gabriella Linville-Engler, Directo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) INVIVYD, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 85-1403134 (State or other jurisdiction of incorporation or organization) 1601 Trapelo Road, Suite 178 Waltham, MA 02451 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR/ 15(d) OF THE SECURITIES EXCHANGE ACT ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-40703 INVIVYD, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 85-14 ...

Invivyd, Inc (NASDAQ:IVVD) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Kyra Faircloth - Investor Relations Dave Hering - Chief Executive Officer Pete Schmidt - Chief Medical Officer Lukas Dillinger - Interim Head, Discovery and Preclinical Fred Driscoll - Interim Chief Financial Officer Conference Call Participants Evan Wang - Guggenheim Sidharth Mehta - Jefferies Operator Thank you for standing by and welcome to the Invivyd 2022 Year End Financial Results Update Call. [O ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40703 INVIVYD, INC. (Exact name of Registrant as specified in its Charter) Delaware 85-1403134 (State or other jurisdiction of Indica ...